Lobbying Filing Details

Total Spending

$2,370,000

Activities

4

Lobbyists

4

Gov't Entities

10

Filing Information
Filing UUID:
42525de2-34b0-4973-9c72-ef16e3524374
Type:
Q3 - 3rd Quarter - Report
Period:
2022 - 3rd Quarter (July 1 - Sep 30)
Date Posted:
October 20, 2022 at 8:05 PM
Income:
$0
Expenses:
$2,370,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Daniel Bachner
Registrant
ABBVIE, INC.

Biopharmaceutical company

Washington, District of Columbia
Client
ABBVIE INC.
District of Columbia, United States of America
Lobbying Activities (4)
Activity 1
Copyright/Patent/Trademark

H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act - provisions related to drug pricing and Medicare Part D H.R. 19, Lower Costs, More Cures Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 & 2023; Notice Requirement for Non-Federal Governmental Plans proposed rule Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
Activity 3
Medicare/Medicaid

Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Taxation/Internal Revenue Code

H.R.5376, Inflation Reduction Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Treasury, Dept of

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.